578 related articles for article (PubMed ID: 17140251)
1. A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.
Takagi T; Ramachandran C; Bermejo M; Yamashita S; Yu LX; Amidon GL
Mol Pharm; 2006; 3(6):631-43. PubMed ID: 17140251
[TBL] [Abstract][Full Text] [Related]
2. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification.
Kasim NA; Whitehouse M; Ramachandran C; Bermejo M; Lennernäs H; Hussain AS; Junginger HE; Stavchansky SA; Midha KK; Shah VP; Amidon GL
Mol Pharm; 2004 Jan; 1(1):85-96. PubMed ID: 15832504
[TBL] [Abstract][Full Text] [Related]
3. Purely in silico BCS classification: science based quality standards for the world's drugs.
Dahan A; Wolk O; Kim YH; Ramachandran C; Crippen GM; Takagi T; Bermejo M; Amidon GL
Mol Pharm; 2013 Nov; 10(11):4378-90. PubMed ID: 24094040
[TBL] [Abstract][Full Text] [Related]
4. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system.
Lindenberg M; Kopp S; Dressman JB
Eur J Pharm Biopharm; 2004 Sep; 58(2):265-78. PubMed ID: 15296954
[TBL] [Abstract][Full Text] [Related]
5. Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number.
Pham-The H; Garrigues T; Bermejo M; González-Álvarez I; Monteagudo MC; Cabrera-Pérez MÁ
Mol Pharm; 2013 Jun; 10(6):2445-61. PubMed ID: 23675957
[TBL] [Abstract][Full Text] [Related]
6. Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs.
Dahan A; Miller JM; Amidon GL
AAPS J; 2009 Dec; 11(4):740-6. PubMed ID: 19876745
[TBL] [Abstract][Full Text] [Related]
7. pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery.
Varma MV; Gardner I; Steyn SJ; Nkansah P; Rotter CJ; Whitney-Pickett C; Zhang H; Di L; Cram M; Fenner KS; El-Kattan AF
Mol Pharm; 2012 May; 9(5):1199-212. PubMed ID: 22489626
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
Jantratid E; Prakongpan S; Amidon GL; Dressman JB
Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
[TBL] [Abstract][Full Text] [Related]
9. Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS).
Fagerholm U
J Pharm Pharmacol; 2007 Jun; 59(6):751-7. PubMed ID: 17637167
[TBL] [Abstract][Full Text] [Related]
10. A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies.
Cristofoletti R; Chiann C; Dressman JB; Storpirtis S
J Pharm Sci; 2013 Sep; 102(9):3136-44. PubMed ID: 23580377
[TBL] [Abstract][Full Text] [Related]
11. Integrating theoretical and experimental permeability estimations for provisional biopharmaceutical classification: Application to the WHO essential medicines.
Cabrera-Pérez MÁ; Pham-The H; Cervera MF; Hernández-Armengol R; Miranda-Pérez de Alejo C; Brito-Ferrer Y
Biopharm Drug Dispos; 2018 Jul; 39(7):354-368. PubMed ID: 30021059
[TBL] [Abstract][Full Text] [Related]
12. Is the full potential of the biopharmaceutics classification system reached?
Bergström CA; Andersson SB; Fagerberg JH; Ragnarsson G; Lindahl A
Eur J Pharm Sci; 2014 Jun; 57():224-31. PubMed ID: 24075971
[TBL] [Abstract][Full Text] [Related]
13. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC.
Tsume Y; Mudie DM; Langguth P; Amidon GE; Amidon GL
Eur J Pharm Sci; 2014 Jun; 57():152-63. PubMed ID: 24486482
[TBL] [Abstract][Full Text] [Related]
14. In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.
Sjögren E; Westergren J; Grant I; Hanisch G; Lindfors L; Lennernäs H; Abrahamsson B; Tannergren C
Eur J Pharm Sci; 2013 Jul; 49(4):679-98. PubMed ID: 23727464
[TBL] [Abstract][Full Text] [Related]
15. Solubility Determination of Active Pharmaceutical Ingredients Which Have Been Recently Added to the List of Essential Medicines in the Context of the Biopharmaceutics Classification System-Biowaiver.
Plöger GF; Hofsäss MA; Dressman JB
J Pharm Sci; 2018 Jun; 107(6):1478-1488. PubMed ID: 29421214
[TBL] [Abstract][Full Text] [Related]
16. The use of drug metabolism for prediction of intestinal permeability (dagger).
Chen ML; Yu L
Mol Pharm; 2009; 6(1):74-81. PubMed ID: 19132929
[TBL] [Abstract][Full Text] [Related]
17. The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation.
Tsume Y; Amidon GL
Mol Pharm; 2010 Aug; 7(4):1235-43. PubMed ID: 20557130
[TBL] [Abstract][Full Text] [Related]
18. Provisional biopharmaceutical classification of some common herbs used in Western medicine.
Waldmann S; Almukainzi M; Bou-Chacra NA; Amidon GL; Lee BJ; Feng J; Kanfer I; Zuo JZ; Wei H; Bolger MB; Löbenberg R
Mol Pharm; 2012 Apr; 9(4):815-22. PubMed ID: 22352942
[TBL] [Abstract][Full Text] [Related]
19. Provisional in-silico biopharmaceutics classification (BCS) to guide oral drug product development.
Wolk O; Agbaria R; Dahan A
Drug Des Devel Ther; 2014; 8():1563-75. PubMed ID: 25284986
[TBL] [Abstract][Full Text] [Related]
20. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests.
Kim JS; Mitchell S; Kijek P; Tsume Y; Hilfinger J; Amidon GL
Mol Pharm; 2006; 3(6):686-94. PubMed ID: 17140256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
